Impax Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
RBC Capital Cuts Price Target on Impax Laboratories (IPXL) Following Unexpected 2Q Miss
August 10, 2016 7:39 AM EDTRBC Capital maintained a Sector Perform rating on Impax Laboratories (NASDAQ: IPXL), and cut the price target to $30.00 (from $35.00), following the company's 2Q earnings report. RBC updated IPXL's model with new 2016-18 EPS estimates of $1.58, $2.24 and $2.46.
Analyst Randall Stanicky commented,... More
Impax Laboratories (IPXL) PT Cut to $24 at Leerink Partners
August 10, 2016 7:08 AM EDTLeerink Partners analyst Jason Gerberry cut his price target on Impax Laboratories (NASDAQ: IPXL) to $24.00 (from $33.00) following a big Q2 miss and "questionable" guidance. The firm maintained a Market Perform rating.
Gerberry commented, "In 2Q, IPXL missed consensus sales and EPS by 25% and 54%, respectively.... More
Impax Laboratories (IPXL) Misses Q2 EPS by 11c; Guides Lower
August 9, 2016 7:05 AM EDTImpax Laboratories (NASDAQ: IPXL) reported Q2 EPS of $0.21, $0.11 worse than the analyst estimate of $0.32. Revenue for the quarter came in at $173 million versus the consensus estimate of $223.67 million.
"Our second quarter results reflect the unexpected and rapid decline in sales of diclofenac and metaxalone as a result of additional competition," said Fred Wilkinson, President and Chief Executive Officer of Impax. "In particular, the change in the diclofenac market quickly moved us from an exclusive supplier position to a five competitor... More
